AARP: Rx prices have reached five-year high

June 2005
Pharmaceutical Representative;Jun2005, Vol. 35 Issue 6, p13
The article reports that the average increase in the price manufacturers charge for brand name prescription drugs has significantly outpaced inflation for the fifth straight year, according to a study from the Washington-based AARP. The study also reports on price changes for 24 of the 25 top-selling brand-name drugs in 2003 that stayed on the market throughout 2004. All but one drug's manufacturer price increase exceeded the 2004 rate of general inflation, and 16 drugs' prices increased at more than double that rate. A study by the Washington-based Pharmaceutical Research and Manufacturers of America, however, shows that prescription drug price increases have been lower than overall medical price increases.


Related Articles

  • Unaffordable Drugs. Kantarjian, Hagop // MIT Technology Review;Nov/Dec2013, Vol. 116 Issue 6, p10 

    The author argues on the need for standard for prices of cancer drugs. He notes that the prices of patented cancer drugs in the U.S. has been increasing since before 2000 by a factor of five to 10. He claims that the unsustainable price increase is affecting patients and the health-care system....

  • What Price Healing? Shanley, Agnes // Pharmaceutical Technology;Nov2016, Vol. 40 Issue 11, p16 

    The article discusses the implications of high pharmaceutical price increases for research and development costs, drug development and manufacturing efficiency. It points out changes in U.S. healthcare insurance landscape, reduced company stock prices and negative public opinion as the major...

  • AARP creates AWP Web site to track drug price increases. Sipkoff, Martin // Drug Topics;6/7/2004, Vol. 148 Issue 11, p45 

    In May 2004, the American Association of Retired Persons set up a Web site comparing pharmaceutical companies' drug price increases with inflation rates. The Web site lists 15 drugs and provides a link to a detailed report by the Public Policy Institute of the AARP listing about 200 drugs by...

  • Appeal to Chancellor.  // Packaging Magazine;11/3/2005, Vol. 8 Issue 20, p4 

    Reports on the impact of the huge hikes in raw materials and energy costs on the manufacturing business in Great Britain. Percentage increase in prices for resins and solvents in the region.

  • UK OUTPUT PRICES.  // Supply Management;3/13/2008, Vol. 13 Issue 6, p57 

    The article reports on the rise in annual output prices for British manufacturers in January 2008. According to the author, petroleum products and food were the main contributors to the price increase which reached 5.7 percent, up from five percent in December 2007. Inflation was 3.1 percent on...

  • MANUFACTURERS' PRICES.  // Supply Management;3/13/2008, Vol. 13 Issue 6, p57 

    The article reports on the Confederation of British Industry's (CBI) claim that manufacturers are planning to raise their prices over the next three months. According to CBI, the price increases will be on food and metal goods. CBI's "Industrial Trends Survey" reported a balance of +22 percent...

  • Price movements. Lerner, Ivan // Chemical Market Reporter;5/30/2005, Vol. 267 Issue 22, p44 

    Presents price increase of products by several industries and firms in the U.S. Announcement of Albemarle Corp. to increase the minimum global price of elemental bromine to 2,000 dollars per metric ton delivered to the end user, effective July 1; Increase of price on Cognis Corp.'s photomer,...

  • Austerity threatens pharma beyond borders of cost cutters. Mullard, Asher // Nature Medicine;Jul2010, Vol. 16 Issue 7, p726 

    The article reports on the cost-cutting schemes in pharmaceutical products and research in Europe. It mentions that government of Greece has initiated to sweep average drug price cuts. It also adds that the coalition government of Great Britain plans to have value-based pricing (VBP) by 2014 to...

  • AARP jousts with PhRMA over drug prices.  // Drug Topics;7/12/2004, Vol. 148 Issue 13, p9 

    AARP charges that drug prices in the U.S. have tripled for the first three months of 2004, while PhRMA claims the drug prices have increased at an equal rate to other healthcare services since the Medicare law was passed in late 2003.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics